Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HY-PAM "25" vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Symptomatic relief of anxiety and tension associated with psychoneurosis,Adjunct in organic disease states with anxiety,Pruritus due to allergic conditions such as chronic urticaria, atopic and contact dermatoses
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (Cr Cl <30 m L/min) and in elderly patients.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Primarily hepatic via CYP3A4 and CYP2D6 isoenzymes; major metabolite is cetirizine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
95-98% bound to albumin and alpha-1-acid glycoprotein.
~20% bound to albumin; minimal binding to other plasma proteins.
0.2-0.3 L/kg, indicating primarily plasma and extracellular fluid distribution.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 60-70% (due to first-pass metabolism); Rectal: 80-90%; Intramuscular: 100%.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific dose recommendation available.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
For Child-Pugh Class A or B, dose reduction to 12.5 mg daily may be considered due to increased exposure; avoid use in Child-Pugh Class C (severe hepatic impairment).
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not established; contraindicated in pediatric patients due to lack of safety and efficacy data.
Not recommended; inadequate safety data.
Start at 12.5 mg daily; maximum dose 25 mg daily due to increased sensitivity and risk of falls, cognitive impairment, and adverse effects.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
May cause QT prolongation, especially in patients with risk factors,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Central nervous system depressant effects may impair mental or physical abilities,Avoid concurrent use with alcohol or other CNS depressants,Use with caution in elderly patients due to increased sensitivity and anticholinergic effects
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to hydroxyzine or any component,Early pregnancy (first trimester) due to potential fetal harm,Porphyria (may precipitate attacks),Concomitant use with monoamine oxidase inhibitors
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
No significant food interactions known.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malformations, but data are limited. Third trimester: Chronic use may cause neonatal withdrawal, floppy infant syndrome (hypotonia, lethargy, feeding difficulties), and respiratory depression at delivery.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Benzodiazepines like HY-PAM 25 are excreted in breast milk. The M/P ratio is approximately 0.5-0.7. With short-acting agents and moderate doses, risk to infant is low but monitor for sedation and poor feeding. Avoid breastfeeding if high maternal doses or chronic use; consider alternative agent.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Increased clearance and volume of distribution in pregnancy may require dose adjustment. For HY-PAM 25, consider increasing the dose by 20-30% in third trimester to maintain efficacy, but taper postpartum to avoid accumulation. Use lowest effective dose and avoid chronic use.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
HY-PAM '25' is a compounded topical formulation containing hydrocortisone 2.5%, pramoxine 1%, and aluminum acetate 0.25%. Use for acute inflammatory dermatoses with pruritus and exudation. Avoid prolonged use on intertriginous areas. Discontinue if signs of skin atrophy or secondary infection develop.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Apply a thin layer to affected areas 3-4 times daily.,Do not use on broken skin, deep wounds, or infected skin without medical guidance.,Avoid contact with eyes and mucous membranes.,Do not cover with bandages or dressings unless directed by your doctor.,Report any worsening of rash, burning, or signs of skin thinning.,Do not use for more than 2 weeks unless directed by your doctor.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HY-PAM "25" vs ALDORIL D50, answered by our medical review team.
HY-PAM "25" is a Antihypertensive Combination that works by Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HY-PAM "25" and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HY-PAM "25" is: 25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HY-PAM "25" and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HY-PAM "25" is classified as Category C. HY-PAM 25 is a benzodiazepine. First trimester: Data suggest an increased risk of oral clefts (approximately 0.6% vs 0.4% background). Second trimester: Possible risk of other malf. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.